| Overview |
| bs-5264R |
| CRK (Ser41) Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Dog, Sheep, Pig, Horse, Rabbit |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human CRK around the phosphorylation site of Ser41 [DS(p-S)TS] |
| Ser41 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 1398 |
| Cytoplasm, Cell membrane |
| p-CRKSer41; p-CRKS41; CRK CRK isoform 2; CRK isoform II; CRKII; p38; Proto oncogene C crk; v crk avian sarcoma virus CT10 oncogene homolog ; v crk sarcoma virus CT10 oncogene homolog; v crk sarcoma virus CT10 oncogene homolog avian; Adapter molecule crk; Avian sarcoma virus CT10 v crk oncogene homolog; CRK_HUMAN. |
| This gene encodes a member of an adapter protein family that binds to several tyrosine-phosphorylated proteins. The product of this gene has several SH2 and SH3 domains (src-homology domains) and is involved in several signaling pathways, recruiting cytoplasmic proteins in the vicinity of tyrosine kinase through SH2-phosphotyrosine interaction. The N-terminal SH2 domain of this protein functions as a positive regulator of transformation whereas the C-terminal SH3 domain functions as a negative regulator of transformation. Two alternative transcripts encoding different isoforms with distinct biological activity have been described. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz